dc.contributor.author |
Perez, Jessica |
|
dc.contributor.author |
Lewis, Katherine A. |
|
dc.contributor.author |
Vargas Rivera, Silver Keith |
|
dc.contributor.author |
Klausner, Jeffrey D. |
|
dc.contributor.author |
Konda, Kelika A. |
|
dc.coverage.spatial |
Lima, Perú |
|
dc.date.accessioned |
2023-12-05T17:47:59Z |
|
dc.date.available |
2023-12-05T17:47:59Z |
|
dc.date.issued |
2023 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/14623 |
|
dc.description.abstract |
BACKGROUND: Sexually transmitted infections (STIs) associated with genital ulcer disease due to herpes simplex virus-2 (HSV-2) are a prominent cause of morbidity and mortality. Serologic screening for HSV-2 is recommended only for individuals with genital herpes symptom history. However, no validated symptom screening tool currently exists. METHODS: Currently asymptomatic adults presenting for routine care at STI clinics in Lima, Peru completed a survey of prior genital herpes symptoms and received HSV-2 serological testing with the Euroimmun Anti-HSV-2 (gG2) ELISA IgG (Lubeck, Germany). A sub-sample of indeterminate results were sent for Western blot confirmatory testing. We assessed associations between past symptoms and anti-HSV-2 positivity and corrected the HSV-2 prevalence by re-classifying indeterminates per Western Blot results. RESULTS: We enrolled 131 participants between July and October 2022. HSV-2 antibody test results found 21.4% positive, 41.2% indeterminate, and 37.4% negative. Excluding indeterminate results, 36.4% were positive. Of participants with no prior symptoms 31.2% tested positive, compared to 35.7% with one prior symptom, 50.0% with 2, and 50.0% with 3+ prior symptoms. Among the sub-sample of indeterminates, 92.6% were confirmed positive by Western Blot, bringing the total estimated proportion of participants with HSV-2 antibodies to 59.5%. Either based on the original classification of HSV-2 antibody status or after incorporation of confirmatory testing results, there was no significant association between symptom history and HSV-2 antibody positivity. CONCLUSIONS: With currently available tests, recommendations to screen individuals based on genital herpes symptom history may not be useful. More discriminatory symptom screening tools or HSV-2 antibody tests with better performance are needed. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
SAGE Publications |
|
dc.relation.ispartofseries |
International Journal of STD and AIDS |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Genital Herpes |
en_US |
dc.subject |
Herpes |
en_US |
dc.subject |
Virus |
en_US |
dc.subject |
Type 2 antibody |
en_US |
dc.subject.mesh |
Herpes Genital |
|
dc.subject.mesh |
Herpes Simple |
|
dc.subject.mesh |
Virus |
|
dc.title |
Does genital herpes symptom history predict herpes simplex virus type 2 antibody positivity? |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1177/09564624231213116 |
|
dc.relation.issn |
1758-1052 |
|